A novel valanimycin-resistance determinant (vlmF) was isolated from a cosmid containing Streptomyces viridifaciens DNA that leads to valanimycin production in Streptomyces lividans. Expression of the vlmF gene in both Escherichia coli and S. lividans provided valanimycin resistance. The nucleotide sequence of vlmF consists of 1206 bp and the deduced amino acid sequence encodes a polypeptide with 12 putative transmembrane-spanning segments and a calculated pI of 101. VlmF shows significant similarities to other known or putative transmembrane efflux proteins that confer antibiotic resistance, but it appears to be specific for valanimycin. The sequence similarities suggest that VlmF is a member of the DHA12 family within the major facilitator superfamily of transport proteins and that it is probably involved in active valanimycin efflux energized by a proton-dependent electrochemical gradient.
INTRODUCTION
The antibiotic valanimycin ( Fig. 1 ) is a naturally occurring azoxy compound isolated from the fermentation broth of Streptomyces viridifaciens MG456-hF10 by Yamato and coworkers (Yamato et al., 1986) . In addition to antibacterial activity, valanimycin exhibits potent cytotoxic activity against in vitro cell cultures of mouse leukaemia L1210, P388\S (doxorubicin-sensitive) and P388\ADR (doxorubicin-resistant) (Yamato et al., 1986) . Valanimycin is a member of a growing family of naturally occurring azoxy compounds, which now includes the cycad toxins macrozamin and cycasin (Lythgoe & Riggs, 1949 ; Langley et al., 1951 ; Riggs, 1956 ; Korsch & Riggs, 1964) , the carcinogen elaiomycin (Stevens et al., 1956 (Stevens et al., , 1958 (Stevens et al., , 1959 , the antifungal agents maniwamycins A and B (Takahashi et al., 1989) , the nematocidal compounds jietacins A and B (Imamura et al., 1989) and the antifungal agent azoxybacilin (Fujiu et al., 1994) . Despite the wide range of biological activity exhibited by this class of natural products, relatively little is known about their mechanisms of action. Investigations of valanimycin suggest that the compound inhibits DNA synthesis and causes induction of DNA repair systems (Yamato et al., 1987) . Previous The GenBank accession number for the sequence in this paper is AF148322.
investigations of valanimycin biosynthesis have established that the antibiotic is derived from -valine and -serine and that valine is converted into valanimycin via the intermediacy of isobutylamine and isobutylhydroxylamine ( Fig. 1) (Parry et al., 1992) . In addition, the conversion of isobutylamine to isobutylhydroxylamine was found to be catalysed by a two-component flavin monooxygenase. The genes (vlmH, vlmR) encoding the two components of this flavin monooxygenase have both been cloned from S. viridifaciens and overexpressed .
In antibiotic-producing organisms, the presence of a self-resistance mechanism is required whenever the antibiotic is potentially harmful to the producer (Cundliffe, 1989) . The self-resistance can be conferred by a number of mechanisms including target modification, antibiotic inactivation or an efflux system (Cundliffe, 1989) . In antibiotic-producing Streptomyces, the genes for antibiotic biosynthesis are generally clustered and are often closely associated with one or more resistance genes (Cundliffe, 1989) . In this report, we describe the cloning of the complete set of genes required for the valanimycin biosynthetic pathway in a low-copy cosmid vector and the characterization of one gene (vlmF) from the cosmid insert that confers valanimycin resistance upon Streptomyces lividans and Escherichia coli. 
METHODS
Strains, plasmids and media. The bacterial strains and plasmids used in this study are indicated in Table 1 . Emerson YpSs agar (Difco) was employed as the sporulation medium for S. lividans. S. lividans protoplasts were prepared and transformed by the procedure of Hopwood et al. (1985) . Conjugation of E. coli S17-1 with S. lividans (Mazodier et al., 1989) was carried out on AS1 agar (Baltz, 1980) using the procedure of Bierman et al. (1992) , with nutrient agar as the top agar. NE agar (10 g -glucose, 2 g Difco yeast extract, 2 g Casamino acids, 1 g Difco beef extract, 15 g agar l − ", pH 7n0) was used for determinations of valanimycin resistance. Thiostrepton, ampicillin, apramycin, kanamycin and spectinomycin were used at final concentrations of 5, 100, 35, 50 and 30 µg ml − ", respectively. Competent E. coli S17-1 cells were prepared by calcium chloride treatment (Sambrook et al., 1989) . DNA methods. Genomic DNA was prepared from S. viridifaciens MG456-hF10 using DNA reagent (Gibco-BRL). Plasmid DNA was purified with a QIAprep spin plasmid kit. DNA fragments were isolated from agarose gels with a QIAquick gel extraction kit. PCR products were separated on agarose gels and purified from the gels. Digestion with restriction endonucleases and ligation experiments were carried out by standard procedures under conditions recommended by the manufacturers. Automated DNA sequencing was performed with an Applied Biosystems DNA sequencer at Lone Star Sequencing Laboratories by using universal and synthetic oligonucleotide primers. Synthetic primers were obtained from Integrated DNA Technologies. The sequence of vlmF was determined by complete sequencing of both DNA strands with multiple sequencing of some regions.
Cosmid library construction and screening. Genomic DNA from S. viridifaciens MG456-hF10 was partially digested with Sau3AI. DNA of the correct size range (35-40 kb) was obtained by digestion for 25 min at 37 mC with aliquots of serially diluted enzyme. The digests were monitored by gel electrophoresis using a FIGE mapper (Bio-Rad). The DNA was then dephosphorylated, and ligated to the two arms generated from digestion of pOJ446 with HpaI, followed by dephosphorylation and digestion with BamHI. The ligation mixture was packaged using MaxPlax Packaging Extract from Epicentre Technologies (Madison, WI, USA). The packaged phages were propagated in E. coli DH10B cells. For library screening, the vlmH gene was removed from plasmid pEIBAH as a 1n1 kb NdeI-XhoI fragment and radiolabelled with [α-$#P]dCTP using the New England Biolabs NEBlot kit. The pOJ446 library was grown on NZYM agar plates (Sambrook et al., 1989) and transferred to Hybond-N nylon membranes (Amersham) in accordance with the manufacturer's instructions. The membranes were probed at 42 mC in 5iSSC and 5iDenhardt's solution. The final wash was in 0n5iSSC, 0n5 % SDS at 59n5 mC for 2 h. Cosmid DNA was isolated from the positive colonies using a QIAprep spin plasmid kit (Qiagen). Competent E. coli S17-1 cells were transformed with isolated cosmid DNA by standard methods (Sambrook et al., 1989) . Cosmids in E. coli S17-1 were introduced into S. lividans TK24 by the procedure of Bierman et al. (1992) .
Analysis of cosmids for valanimycin production. S. lividans TK24 strains containing cosmids recovered from the cosmid library by screening with the vlmH gene were fermented in valanimycin production medium according to the procedure of Yamato et al. (1986) . After approximately 40 h, the mycelium was removed by centrifugation, and the fermentation broth was acidified to pH 3. The acidified broth was extracted twice with ethyl acetate. The combined ethyl acetate extracts were concentrated to a small volume in vacuo and examined for the presence of valanimycin by TLC (silica gel ; chloroform\methanol\acetic acid, 200 : 40 : 1), with UV detection. Several cosmid-containing strains appeared to produce valanimycin in varying amounts, while the fermentation broth derived from S. lividans containing pOJ446 failed to show the presence of valanimycin. The highest producing strain, which contained pVal38, was selected for further study. The fermentation of S. lividans containing pVal38 was carried out on a larger scale and the putative valanimycin was isolated by ethyl acetate extraction and purified by chromatography on Dowex 1X8 (Cl − ) (Yamato et al., 1986) . Since purified valanimycin is somewhat unstable, the solution of valanimycin in ethyl acetate obtained after purification was taken to dryness in vacuo below room temperature. The residue was immediately dissolved in CDCl $ and the solution was analysed by "H NMR spectrometry. The proton NMR spectrum verified that valanimycin had been produced ( Table  2) .
Subcloning of the vlmF gene. Screening of the valanimycinproducing strain S. lividans TK24(pVal38) for valanimycin resistance as described below revealed that S. lividans TK24(pVal38) was significantly more resistant to valanimycin than S. lividans containing the parent vector pOJ446. Digestion of pVal38 with EcoRI gave a 15 kb fragment derived from the insert in pVal38 (Fig. 2) . When this 15 kb fragment was cloned into EcoRI-digested pKC1218 (Bierman et al., 1992), the resulting plasmid (pVal15) was found to confer valanimycin resistance on S. lividans. Digestion of the 15 kb fragment with EcoRV yielded an 11n9 kb fragment which was cloned into EcoRV-digested pKC1218 to give pVal12 (Fig. 2) . When pVal12 was introduced into S. lividans, it also conferred valanimycin resistance, indicating the presence of one or more resistance genes on this fragment.
Construction of expression plasmids. In order to facilitate the cloning of the vlmF gene into the expression vectors pRSETB and pWHM1109, PCR primers were designed to allow the introduction of EcoRI and HindIII sites. For pRSETB, the sequences of the forward and reverse primers were GG-CGAATTCATGACGACGGAACCACTGGC and GTA-AAGCTTTTAGGTGAGCTCGCGTCGCT, respectively. The EcoRI and HindIII sites, respectively, are underlined. For pWHM1109, the sequences for the forward and reverse primers were GGCAAGCTTATGACGACGGAACCACTG-GC and GTAGAATTCTTAGGTGAGCTCGCGTCGCT, respectively. The HindIII and EcoRI sites, respectively, are underlined. By means of these restriction sites, the PCR products were cloned into pRSETB and pWHM1109 cut with the same endonucleases. PCR was carried out in a 50 µl reaction volume with a 1 : 1 mixture of (Kyte & Doolittle, 1982) . The DNA Strider program was occasionally used for sequence analysis.
Preparation of valanimycin and valanimycin-containing NE agar. Streptomyces viridifaciens MG456-hF10 was fermented according to the published procedure. The antibiotic was purified by anion-exchange chromatography on Dowex 1X8 (Cl − ). The solution of valanimycin in ethyl acetate obtained after purification was taken to dryness in vacuo below room temperature in a tared flask, and the weight of the valanimycin was determined immediately after removal of traces of solvent under high vacuum. The residue was then immediately dissolved in 10 mM sodium phosphate solution, pH 7n0, and aliquots of the resulting solution were added to warm NE agar before pouring plates.
Determination of MICs of valanimycin and other antibiotics.
E. coli cells and S. lividans spores were inoculated onto NE agar plates containing varying amounts of valanimycin, tetracycline or puromycin. S. lividans containing pVal2 was grown at 30 mC in the presence of thiostrepton (5 µg ml − ") to induce vlmF expression. E. coli NovaBlue(DE3)(pVal3) was grown at 37 mC in the presence of 1 mM IPTG to induce vlmF expression. Growth was scored after overnight incubation with E. coli and after 3 d with S. lividans.
RESULTS

Isolation of valanimycin-producing cosmids
A cosmid library containing S. viridifaciens DNA was constructed in the cosmid shuttle vector pOJ446 (Bierman et al., 1992) using fragments derived by partial digestion of genomic DNA with Sau3AI. Screening of the library with a $#P-labelled probe derived from the vlmH gene identified 14 hybridizing clones out of approximately 1000 clones. Cosmid DNA from each of the hybridizing clones was introduced into E. coli S17-1 by transformation and then transferred from S17-1 to S. lividans TK24 by conjugation (Bierman et al., 1992) . Each cosmid-containing S. lividans clone was fermented in valanimycin production medium, and ethyl acetate extracts of the culture medium were analysed for the presence of valanimycin by TLC with visualization by UV light. Several cosmid-containing clones appeared to produce valanimycin. The clone that appeared to produce the highest levels of valanimycin was selected for additional study. A large-scale fermentation of this clone, pVal38, allowed isolation and purification of a compound that was shown to be valanimycin by TLC and "H NMR analysis. The "H NMR data for valanimycin isolated from S. viridifaciens and from S. lividans TK24(pVal38) are compared in Table 2 .
Cloning and sequencing of the valanimycinresistance gene (vlmF)
S. lividans TK24 containing pVal38 was screened for valanimycin resistance on NE agar. This clone was found to be more resistant to valanimycin than S. lividans TK24 and S. lividans TK24 carrying the parent vector pOJ446 (Table 3 ). Analysis of pVal38 by digestion with several restriction endonucleases revealed that a 15 kb fragment internal to the cosmid insert could be generated by treatment with EcoRI (Fig. 2) . This fragment was subcloned into the E. coli-Streptomyces shuttle vector pKC1218 (Bierman et al., 1992) to give pVal15. Introduction of pVal15 into S. lividans TK24 
* Thiostrepton (5 µg ml −" ) was added to induce expression. † IPTG (1 mM) was added to induce expression. ‡ j\k, Growth is poor.
conferred the same level of valanimycin resistance as did pVal38 (Table 3) , a result suggesting that the valanimycin-resistance gene resides on the 15 kb EcoRI fragment. Digestion of the 15 kb fragment with EcoRV yielded a 12 kb fragment that was cloned into pKC1218 to give pVal12. Introduction of pVal12 into S. lividans conferred the same level of valanimycin resistance as pVal38 and pVal15 (Table 3) . In order to locate the valanimycin-resistance gene(s), the insert in pVal12 was sequenced. Sequencing revealed the presence of vlmH and vlmR as well as several potential ORFs. The translated amino acid sequence of one of these (vlmF) exhibited similarities to known antibiotic-resistance determinants. The vlmF gene was located approximately 6n4 kb downstream of vlmH and was transcribed in the same direction. vlmF was found to consist of 1206 bp and to encode a polypeptide of 402 amino acids. The vlmF gene exhibited an overall GjC content of 70n4 mol %, with a mean GjC content at the third codon position of 90n0 mol %. These values are typical for Streptomyces genes (Wright & Bibb, 1992) . The sequence CGAGGA was found about seven nucleotides 5h to the first codon of the vlmF gene. This sequence exhibits a significant degree of complementarity to the 3h end of 16S rRNA of S. lividans and it could serve as a ribosome-binding site (Bibb & Cohen, 1982) . The calculated molecular mass of the vlmF gene product was 41 015 Da, and the calculated isoelectric point was 10n1.
Expression of the vlmF gene product and assays for antibiotic resistance
To establish that the putative vlmF gene encodes a protein conferring valanimycin resistance, a DNA fragment containing the gene was amplified from pVal38 by PCR and subcloned into the Streptomyces expression vector pWHM1109 (Tang et al., 1996) and the E. coli expression vector pRSETB to give plasmids pVal2 and pVal3. The plasmids were amplified in E. coli DH10B and then transformed into S. lividans TK24 and E. coli NovaBlue(DE3), respectively. S. lividans TK24(pVal2) and E. coli NovaBlue(DE3)(pVal3) were grown on NE agar in the presence of varying amounts of valanimycin. In the case of S. lividans TK24(pVal2), thiostrepton was added to the agar at 5 µg ml −" to induce vlmF expression from the tipA promoter (Tang et al., 1996) . E. coli NovaBlue(DE3)(pVal3) was grown in the presence of 1 mM IPTG to induce vlmF expression. The results (Table 3) show that VlmF confers a substantial degree of resistance to valanimycin on both S. lividans and E. coli. E. coli (DE3)(pVal3) and S. lividans TK24(pVal2) were also assayed for resistance to tetracycline and puromycin. Neither clone exhibited enhanced resistance to either antibiotic (data not shown).
Sequence homology studies
,  and  analyses of vlmF revealed a significant degree of similarity between VlmF and the tetracycline [TetA(H)] and puromycin (Pur8) resistance proteins as well as a number of putative efflux proteins (Fig. 3) . A hydropathy plot of VlmF using the amino acid hydropathy values of Kyte and Doolittle (Kyte & Doolittle, 1982) indicated that VlmF is a transmembrane protein (Fig. 4) . A  comparison of VlmF with TetA(H) and Pur8 indicated that the greatest similarity between these proteins lies within their N-terminal regions (data not shown). Conserved residues between transmembrane domains 2 and 3 are shaded. The abbreviations and accession numbers for the aligned proteins are : YegB, hypothetical protein in alka-baes intergenic region from Escherichia coli (P36554) ; YnfM, hypothetical protein in mlc-asr intergenic region from Escherichia coli (P43451) ; Pur8, puromycin-resistance protein from Streptomyces lipmanii (P42670) ; TetA(H), tetracycline-resistance protein, class H, from Pasteurella multocida (P51564) ; NapC, putative tetracycline efflux protein from Enterococcus hirae (AJ000346) ; st-Hyp1, hypothetical chloramphenicol and florfenicol resistance protein (fragment) from Salmonella typhimurium (AF097407) ; SuxA, bicyclomycin and sulfonamide resistance protein from Escherichia coli (P28246).
DISCUSSION
A library of genomic DNA from the valanimycin producer S. viridifaciens in the cosmid shuttle vector pOJ446 was screened with an S. viridifaciens gene (vlmH) that is believed to be required for valanimycin biosynthesis . When one of the positively hybridizing cosmid clones (pVal38) recovered from the screening was introduced into S. lividans TK24, the resulting strain produced valanimycin when grown in valanimycin production medium. This suggests that cosmid pVal38 carries all of the genes required for the biosynthesis of valanimycin on a 38 kb fragment. However, the possibility that one or more S. lividans genes is used in the production of valanimycin by this organism cannot be ruled out.
It is now well established that antibiotic-producing micro-organisms carry antibiotic self-resistance genes in order to avoid the lethal effects of their own toxins and, further, that the resistance genes are often closely associated with the corresponding biosynthetic genes. S. lividans containing cosmid pVal38 was therefore evaluated for resistance to valanimycin. The recombinant strain was found to be resistant to valanimycin at twice the concentration of the host organism (Table 3) . In a control experiment, the presence of cosmid vector pOJ446 did not affect the level of resistance exhibited by the host. Subcloning experiments combined with resistance screening localized the valanimycin-resistance determinant to a 12 kb EcoRV fragment. Sequencing of this fragment revealed the presence of an ORF (vlmF) exhibiting similarities to known antibiotic-resistance genes and to several hypothetical efflux proteins (see below). When vlmF was cloned into the E. coli and Streptomyces expression vectors pRSETB and pWHM1109, the resulting constructs (pVal3, pVal2) conferred valanimycin resistance on E. coli and S. lividans in the presence of the inducers IPTG and thiostrepton, respectively. In the case of E. coli, pVal3 conferred a level of valanimycin resistance that was at least 10 times greater than that tolerated by the same E. coli strain carrying pRSETB (Table 3) . S. lividans carrying pVal2 was resistant to levels of valanimycin at least four times greater than those acceptable to S. lividans containing pWHM1109 (Table 3) .
,  and  analyses of vlmF revealed a significant degree of similarity between VlmF and the tetracycline [TetA(H)] and puromycin (Pur8) resistance proteins as well as between VlmF and a number of putative efflux proteins (Fig. 3) . A hydropathy plot of VlmF using the amino acid hydropathy values of Kyte and Doolittle indicates that VlmF is a transmembrane protein with 12 putative transmembrane-spanning domains (Fig. 4) . These properties suggest that VlmF is a member of the DHA12 family within the major facilitator superfamily of transport proteins (Pao et al., 1998) . This assignment is supported by the absence in VlmF of the H motif that is found in the DHA14 family of transport proteins (Paulsen et al., 1996) . It is of interest that VlmF exhibits similarities to both TetA(H) and Pur8, since TetA(H) is a member of the DHA12 family, while Pur8 is a member of the DHA14 family (Paulsen et al., 1996 ; Pao et al., 1998) . VlmF contains part of the β-turn motif [RK]-X-G-R- [RK] which is found between transmembrane domains 2 and 3 in most eukaryotic and prokaryotic transport proteins (shaded in Fig. 3 ) (Henderson & Maiden, 1990) . It also contains the Ser-Asp dipeptide (shaded in Fig. 3 ) that is conserved in all known tetracycline antiporter proteins (Yamaguchi et al., 1990) . In addition, VlmF contains a conserved glycine residue (Gly(') that is found in all tetracycline\H + antiporters and sugar transporters (Yamaguchi et al., 1992) . While relatively little is known about the mechanism of action of valanimycin, the available information suggests that it damages DNA (Yamato et al., 1987) . The structure of valanimycin suggests it may be a DNA alkylating agent since the antibiotic contains an electrophilic dehydroalanine moiety. An additional mechanism of action might involve reaction of the dehydroalanine moiety of valanimycin with protein cysteine residues (Chiu et al., 1996) . A drug efflux protein such as VlmF may be the simplest way for an organism to protect its DNA or proteins against an electrophilic agent such as valanimycin.
Our investigations have shown that VlmF does not confer resistance to either tetracycline or puromycin on S. lividans, even though it exhibits similarities to TetA(H) and Pur8. This is consistent with other studies that have shown that the resistance phenotype conferred by Pur8 on S. lividans is specific for puromycin (Tercero et al., 1993) . An inspection of the multiple sequence alignment shown in Fig. 3 reveals that most of the similarities between VlmF and other efflux proteins lie in the N-terminal region. This is confirmed by a \ analysis (data not shown). The lack of strong similarity between the C-terminal regions of VlmF, TetA(H) and Pur8 as revealed by the  has been observed for other antibiotic efflux proteins (Tercero et al., 1993) . It may indicate that the Cterminal end of these proteins confers drug-binding specificity (Paulsen et al., 1996) . sequence analysis. We thank Sao Jiralerspong for helpful discussions.
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